Entrada Therapeutics, Inc. (TRDA) Financial Analysis & Valuation | Quarter Chart
Entrada Therapeutics, Inc. (TRDA)
TRDAPrice: $12.38
Fair Value: 🔒
🔒score
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead ... more
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therape... more
Description
Shares
| Market Cap | $473.35M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Dipal Doshi |
| IPO Date | 2021-10-29 | CAGR | — |
| Employees | 183 | Website | www.entradatx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.03% | Total Yield | -0.03% |
TRDA chart loading...
Fundamentals
Technicals
| Enterprise Value | $385.84M | P/E Ratio | -2.69 |
| Forward P/E | -4.08 | PEG Ratio | — |
| P/S Ratio | 18.62 | P/B Ratio | 1.67 |
| P/CF Ratio | -3.99 | P/FCF Ratio | -3.65 |
| EPS | $-2.57 | EPS Growth 1Y | -282.03% |
| EPS Growth 3Y | 22.18% | EPS Growth 5Y | -68.79% |
| Revenue Growth 1Y | -87.94% | Gross Margin | -0.56% |
| Operating Margin | -6.21% | Profit Margin | -5.65% |
| ROE | -0.4% | ROA | -0.38% |
| ROCE | -0.45% | Current Ratio | 12.53 |
| Quick Ratio | 12.53 | Cash Ratio | 3.7 |
| Debt/Equity | 0.17 | Interest Coverage | — |
| Altman Z Score | 2.72 | Piotroski Score | 2 |